Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
Flattish volume growth and subdued new launches were key factors for last month
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The segment delivered strong sales growth of 20% YoY
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
Subscribe To Our Newsletter & Stay Updated
